Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma
Ronald M BukowskiCleveland Clinic Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH, USAAbstract: The management of renal cell carcinoma (RCC) has undergone significant changes during the past 10 years, with the treatment of metastatic RCC undergoing the most radical changes. These d...
Main Author: | Bukowski RM |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2011-08-01
|
Series: | Cancer Management and Research |
Online Access: | http://www.dovepress.com/critical-appraisal-of-pazopanib-as-treatment-for-patients-with-advance-a8046 |
Similar Items
-
Pazopanib for the Treatment of Patients with Advanced Renal Cell Carcinoma
by: Joshua M. Lang, et al.
Published: (2010-01-01) -
Pazopanib in the treatment of advanced renal cell carcinoma
by: David Cella, et al.
Published: (2016-02-01) -
Pazopanib in the treatment of advanced renal cell carcinoma
by: M. I. Volkova, et al.
Published: (2018-11-01) -
The prospects of pazopanib in advanced renal cell carcinoma
by: Shilpa Gupta, et al.
Published: (2013-10-01) -
Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
by: Ridhima Iyer, et al.
Published: (2017-01-01)